View ValuationRetinalGenix Technologies 将来の成長Future 基準チェック /06現在、 RetinalGenix Technologiesの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Medical Equipment 収益成長16.1%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 16RetinalGenix Technologies Inc. announced delayed 10-Q filingOn 05/15/2026, RetinalGenix Technologies Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Mar 31RetinalGenix Technologies Inc. announced delayed annual 10-K filingOn 03/30/2026, RetinalGenix Technologies Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jan 14RetinalGenix Technologies Inc. Reports on Its Science and Mission in Light of New AI-Driven Retinal Mapping StudyRetinalGenix Technologies Inc. announced that a recent large-scale Australian retinal mapping study, which used artificial intelligence to analyze approximately 50,000 retinal scans, reported that specific patterns of retinal thinning are associated with neurodegenerative and metabolic diseases such as dementia, diabetes, and multiple sclerosis. These findings support the broader field of oculomics and reinforce the premise that high-quality retinal images, analyzed with advanced algorithms and integrated with genetic and clinical data, could become an important tool for earlier detection, risk stratification, and ongoing monitoring of disease. If successfully developed, validated, and cleared, these platforms could enable the generation of large-scale, real-world retinal datasets from pharmacies, clinics, urgent care centers, nursing homes, and potentially in-home environments. Such a distributed imaging network could create opportunities for AI-enhanced screening, earlier identification of disease signals, and more proactive patient management, while also providing valuable datasets for research and partnerships with payers, providers, and life sciences companies. The same scientific trends that support the Australian study--convergence of imaging, AI, and genomics--also support RetinalGenix's broader strategy, including programs in remote diagnostics, pharmacogenetic mapping, and therapeutics for conditions such as dry AMD and Alzheimer's-related dementia.お知らせ • Dec 09+ 1 more updateRetinalGenix Technologies Inc. Appoints M. Cory Zwerling as Chief Financial Officer, Effective January 1, 2026RetinalGenix Technologies Inc. has agreed to hire M. Cory Zwerling as its Chief Financial Officer, effective January 1, 2026. Mr. Zwerling brings more than three decades of global experience in healthcare, finance, and operations across pharmaceuticals, medical imaging, biotechnology, and digital health. Mr. Zwerling brings a distinctive combination of big-pharma P&L leadership, public-company governance, Medtech start-up execution, and hands-on CFO experience across healthcare technology. He has led global pharmaceutical and imaging divisions (President, Bristol-Myers Squibb Medical Imaging and other roles over his 18-year tenure at Bristol-Myers), founded and operated a healthcare IT/AI sleep-diagnostics company (CEO & co-founder, Serenium Inc), served as CEO of a medical-device venture (Zosano Pharmaceuticals), advised multiple health-technology companies, and held a public-company board seat. His background aligns directly with RetinalGenix’s strategic inflection point as the Company seeks to transition from R&D into early commercial operations. His leadership in global marketing, sales, international business management, and finance makes him uniquely equipped to guide the Company through its intended commercial launch while working to ensure disciplined capital deployment and long-term shareholder value creation.お知らせ • Aug 15RetinalGenix Technologies Inc. announced delayed 10-Q filingOn 08/14/2025, RetinalGenix Technologies Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Feb 21Retinalgenix Technologies Breakthrough in Real-Time 24/7 Remote Ocular MonitoringRetinalGenix Technologies Inc. announced that it has achieved an important milestone in developing its high-resolution retinal imaging device and remote monitoring system. The Company has successfully started imaging patients with its first prototype of its device using both near-infrared and green modes. Additionally, the imaging device simultaneously captures retinal and external images of the patient's eye. A specialized network of retinal specialists will be available to receive the images on a contracted basis, assisting patients who may currently lack an eye care professional to review their results. The device is not intended for diagnostic purposes; rather, it is a screening and monitoring tool. Ex Including patients who are unsuitable for the injections and unlikely to benefit, could avoid any unnecessary complications or morbidity while effectively reducing healthcare expenses. The test should be available to patients at a reasonable cost of approximately $355.00. These factors would make the test invaluable. Over 8 million intraocular injections are performed annually in the United States. Dry AGE-RELATED MACULAR DEGENERATION (AMD) The dry type of AMD affects about 18 million people. It can be painful; infections are common and there is no FDA-approved treatment at this time. The RetinalGenix™? high-resolution retinal imaging system is designed to enable screening for dry macular degeneration in a matter of moments. The scan may be able to assess the severity of the AMD and whether or not it could rapidly progress to the wet type of AMD. RetinalGenix also has been implementing its strategy to identify several opportunities to repurpose FDA-approved pharmaceuticals for the potential benefit of Dry AMD, diabetic retinopathy, and dementia. The Company has submitted provisional patents for these indications in the US and Europe.お知らせ • Nov 14RetinalGenix Technologies Inc. announced delayed 10-Q filingOn 11/13/2024, RetinalGenix Technologies Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 15RetinalGenix Technologies Inc. announced delayed 10-Q filingOn 08/14/2024, RetinalGenix Technologies Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 18RetinalGenix Technologies Inc. announced delayed 10-Q filingOn 05/16/2024, RetinalGenix Technologies Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Dec 21RetinalGeniX Technologies Inc. Appoints Anatoly Dritschilo, M.D. to the Medical Advisory BoardRetinalGeniX Technologies Inc. announced that Anatoly Dritschilo, M.D. has joined the Company’s Medical Advisory Board. Dr. Dritschilo is a renowned educator, inventor, translational scientist, and business executive. Dr. Dritschilo is the CEO and Chairman of the Board of Directors of Shuttle Pharmaceuticals Holdings Inc. Formerly, as an educator and translational scientist, he was employed at the Georgetown University and the MedStar Georgetown University Hospital as a radiation oncologist and chairman of the Department of Radiation Medicine. Over a 40+ year career, he has provided clinical services to thousands of patients presenting with cancers of the breast, prostate, and the central nervous system. As a translational scientist, Dr. Dritschilo has focused his research on sensitizing cancers to ionizing radiation. He is a leader in the development of antisense oligonucleotides and small molecules directed at targets for radiation sensitization. He has also served as Medical Director of Georgetown University Hospital from 1994 to 1997, and Interim Director of the NCI-funded Lombardi Comprehensive Cancer Center from 2005 to 2007. He has been a member of the Boards of Directors of MedStar-Georgetown University Hospital, the National Capital Rehabilitation Hospital, and the MedStar Research Institute. His 250+ scientific publications and 12 issued patents have earned him election as a Fellow of the National Academy of Inventors. Dr. Dritschilo holds a BS degree in Chemical Engineering from the University of Pennsylvania, his medical degree from the College of Medicine of New Jersey, and residency training from the Harvard Joint Center for Radiation Therapy.お知らせ • Dec 05RetinalGeniX Technologies Inc. Appoints Dessislava Boneva to its Board of DirectorsRetinalGeniX Technologies Inc. announced that Dessislava (Dessy) Boneva, M.D. has joined the Company’s Board of Directors. Dr. Boneva is an experienced surgeon skilled in trauma, surgical critical care, emergency surgery, and acute care surgery. Dr. Boneva's career began at a specialized Mathematics school where she excelled in Engineering. However, it wasn't until she went on health mission trips that she discovered her true passion for helping patients. She decided to pursue a career in medicine and trained at some of the best schools in the U.S. After completing her surgical residency at an Ivy League school, she was fortunate enough to be trained by some of the best trauma surgeons and leaders in her field, both in the U.S. and around the world. She has dedicated her life to saving lives and helping patients recover from traumatic injuries. With over 10,000 surgeries under her belt, more than 100 publications, and over 20 years of experience in her specialty, she remains just as devoted to the profession as she was when she first started. Dr. Boneva is a faculty member at the University of South Florida (USF) and has received numerous awards throughout her career. She has been included in the Dean's Honor's List, National Dean's List, and Who's Who among students in American Universities and Colleges, as well as the International Who's Who of Professionals. She is actively involved in educating students, residents, and critical care fellows as part of the Graduate Medical Education (GME) programs at her hospital. She is also a Fellow of the American College of Surgeons.お知らせ • Dec 02RetinalGenix Technologies Inc. Appoints Virender Ahluwalia as Interim Chief Financial OfficerRetinalGeniX Technologies Inc. announced that it has hired Virender Ahluwalia as Interim Chief Financial Officer. Mr. Ahluwalia is a seasoned executive and joins RetinalGeniX Technologies Inc. with over 15 years of experience in finance and operations across public and private organizations. He holds an MBA in Finance from Northeastern University and a Bachelor of Science from the National Institute of Technology (NIT) at Kurukshetra University. His proven track record in high-growth environments includes capital raises and accounting. RetinalGeniX is developing innovative technologies such as DNA/RNA/GPS™ Pharmaco-Genetic Mapping™ software to prevent blindness through the early detection and treatment of ocular diseases.お知らせ • Nov 29RetinalGenix Technologies Inc. Appoints Stephen Tannenbaum to the Business Advisory BoardRetinalGeniX™ Technologies Inc. announced the addition of Stephen Tannenbaum to the Business Advisory Board of RetinalGeniX. Mr. Tannenbaum will provide strategic business advice, consult on potential mergers and acquisitions, and the development of channels to acquire additional capital for the Company. Mr. Tannenbaum is a seasoned professional in capital markets with a proven track record in raising both equity and debt for public and private companies in special situations. His expertise lies in crafting compelling narratives for capital raises and utilizing resources and knowledge to offer strategic and actionable advice. As a versatile generalist, he has successfully advised and closed transactions across diverse industries, including but not limited to technology, pharmaceuticals, and cannabis. Throughout his investment banking career, he played a pivotal role in raising capital for M&A, equity and debt capital markets, IPOs, and SPACs, specializing in the pharmaceutical and cannabis sectors. He is a distinguished graduate with honors from The Wharton School of The University of Pennsylvania, bringing a unique blend of academic excellence and real-world financial acumen to the table.お知らせ • Nov 11RetinalGeniX Technologies Inc. Announces the Submission of Two Provisional Patent Applications for Investigational Therapeutic DrugsRetinalGenix Technologies Inc. announced that it has submitted two provisional patent applications to the US Patent Office for its investigational therapeutic drug candidates RTG-2023 and RTG-2024. RTG-2023 is being developed to treat dry age-related macular degeneration (AMD). There are two forms of the disease; wet AMD and dry AMD. Wet macular degeneration is the leading cause of permanent central vision loss. Dry AMD can progress to the wet type if not monitored closely by a doctor. Currently, there are no drugs approved by the FDA that can prevent the dry form of this eye disease from progressing to the wet form or treat the wet form, except through intraocular injections. These direct injections into the eyes are a heavy burden on the patient, both financially and emotionally, and must be administered monthly for the rest of their life. A 2022 study displayed by the National Institutes of Health (NIH PubMed) stated that 200 million people worldwide are estimated to have AMD, and by 2040, this number is projected to rise to close to 300 million. According to the Centers for Disease Control, in 2019, an estimated 19.8 million (12.6%) Americans aged 40 and older were living with age-related macular degeneration (AMD). Of these, 1.49 million (0.94%) were living with (the) vision-threatening (form) RTG-2024 is intended for the treatment of dementia, specifically Alzheimer’s syndrome. According to Alzheimer's Disease International (“ADI”), there are over 55 million people worldwide living with dementia in 2020 and this number is expected to almost double every 20 years, reaching 78 million in 2030 and 139 million in 2050. ADI estimates there are over 10 million new cases of dementia each year worldwide, implying one new case every 3.2 seconds.お知らせ • Nov 01RetinalGeniX Technologies Inc. Announces Institutional Review Board Approves to Conduct Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular DegenerationRetinalGeniX Technologies Inc. announced the launch of an Institutional Review Board (IRB) for research on its DNA/GPS program. The study aims to offer recommendations for enhancing the preselection process and management of ocular injections. The proposed patient selection process has the potential to reduce the cost and improve the safety and efficacy of patient candidate selection for ocular injections. These factors represent significant challenges associated with wet macular degeneration-related vision loss.お知らせ • Aug 29RetinalGenix Technologies Inc. Appoints Fred Chasalow to the Medical Advisory Board of DNA-GPSRetinalGenix Technologies Inc. announced the addition of Fred Chasalow, Ph.D., to the Medical Advisory Board of DNA-GPS™. He will also advise RTGN on its other corporate activities. In this capacity, specifically, he will (a) participate in therapeutic drug selection and development and (b) assist in linking high-resolution retinal imaging (RetinalCam™) both to systemic disease and to DNA-GPS™ pharmacogenetic mapping. Dr. Chasalow earned his Ph.D. in biochemistry at Brandeis University. He served as a post-doctoral fellow at ALZA and then as a Senior Research Associate at Columbia P&S with Dr. Seymour Lieberman. From 1977 to 1995, Dr. Chasalow served at several academic appointments, finally ending as Professor of Pediatrics at SUNY, Brooklyn, and Chief of Pediatric Research at Maimonides Medical Center and Director of its Pediatric Endocrine Laboratory. During this period, much of his research included establishing diagnostic methods appropriate for small samples available from infants. In 1991, Dr. Chasalow was appointed as a member of the SuperGen Scientific Advisory Board and played a key role in the scientific development of SuperGen, leading to its successful IPO in 1996. His business experience includes a short stint as an Associate Vice President at Morgan Stanley and 15 years as an independent financial advisor. In 1995, Dr. Chasalow was one of the founders of AMUR Research. It was in his capacity as Chief Scientific Officer that Dr. Chasalow started the investigation that led to the discovery of three novel steroids. Later, AMUR was sold to SuperGen. In 2015, Dr. Chasalow founded IOMA LLC. At IOMA, Dr. Chasalow is credited with discovering three novel steroids. These play a key role in the disease process leading to pre-eclampsia syndrome and, potentially, may lead to its therapy. This spring, Dr. Chasalow sold IOMA to Coddle Creek Capital, where he continues to serve as a consultant.お知らせ • May 17RetinalGenix Technologies Inc. announced delayed 10-Q filingOn 05/16/2023, RetinalGenix Technologies Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Nov 16RetinalGenix Technologies Inc. announced delayed 10-Q filingOn 11/15/2022, RetinalGenix Technologies Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 16RetinalGenix Technologies Inc. announced delayed 10-Q filingOn 08/15/2022, RetinalGenix Technologies Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jul 27RetinalGenix Technologies Inc. Appoints Vinay Mehindru to its Board of DirectorsRetinalGenix Technologies Inc. announced the appointment of Vinay Mehindru, MD, MBA to the RetinalGenix Technologies Inc. Board of Directors. Dr. Mehindru is a multi-talented top-level executive with over 25 years of healthcare experience. His leadership spans population health and financial performance management. He has led multiple physician performance enhancement strategies and built stakeholder alliances with clinical and financial integration. He is currently serving on the board of directors of Sanovas Inc., SteriView™ Technologies Inc., Intubation Science™, Inc, SinuGeniX™ Inc., OtoGeniX™ Inc., PulmoGeniX™ Technologies Inc., and GastroGeniX™ Inc. Graduating from medical school at age 21, Dr. Mehindru was one of the youngest graduates in his country of birth, India. At age 27, he served on the faculty of the Cleveland Clinic where he was a top-tier internal medicine resident and did research in gastroenterology. Vinay has a second residency from the University of Florida in emergency medicine. Vinay joined a private group of emergency physicians on the east coast of Florida with 47 providers, 75 employees, and over 100,000 annual visits. He has tremendous experience in airway management; working at a level-two trauma center for 10 years. For 16 years, he had been an instructor teaching difficult airway management for both cardiovascular life support and pediatric advanced life support. At the University of Texas at Dallas, he received an Executive MBA with honors, earning the Beta Gamma Sigma Award offered only to the world’s top 5% of business students. Dr. Mehindru is the Founder & CEO of Exemplary Health. With AdventHealth he has been a Chief Medical Officer and was President of AdventHealth’s Physician Network, Tampa Bay.お知らせ • Jul 08RetinalGenix Technologies Inc. (OTCPK:RTGN) acquired DNA/GPS Inc. from Lawrence Perich.RetinalGenix Technologies Inc. (OTCPK:RTGN) acquired DNA/GPS Inc. from Lawrence Perich for $14 million on July 5, 2022. RetinalGenix Technologies Inc. acquired all the outstanding shares of DNA/GPS Inc. in exchange for the issuance of 2,000,000 shares of the Company’s common stock. Larry Perich, Founder of DNA/GPS Inc., will join the advisory board of RetinalGenix Technologies Inc. Leslie Marlow of Blank Rome LLP acted as legal advisor to RetinalGenix Technologies Inc. Ken Zuckerbrot of Greenberg Traurig, LLP acted as legal advisor to DNA/GPS Inc. RetinalGenix Technologies Inc. (OTCPK:RTGN) completed the acquisition of DNA/GPS Inc. from Lawrence Perich on July 5, 2022.お知らせ • Apr 01RetinalGenix Technologies Inc. announced delayed annual 10-K filingOn 03/31/2022, RetinalGenix Technologies Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、RetinalGenix Technologies は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:RTGN - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2026N/A-200N/A12/31/2025N/A-2-1-1N/A9/30/2025N/A-3-1-1N/A6/30/2025N/A-3-1-1N/A3/31/2025N/A-3-1-1N/A12/31/2024N/A-4-1-1N/A9/30/2024N/A-4-1-1N/A6/30/2024N/A-4-1-1N/A3/31/2024N/A-4-1-1N/A12/31/2023N/A-200N/A9/30/2023N/A-200N/A6/30/2023N/A-400N/A3/31/2023N/A-400N/A12/31/2022N/A-400N/A9/30/2022N/A-400N/A6/30/2022N/A-2-1-1N/A3/31/2022N/A-2-1-1N/A12/31/2021N/A-2-1-1N/A9/30/2021N/A-2-1-1N/A6/30/2021N/A-2-1-1N/A3/31/2021N/A-2-1-1N/A12/31/2020N/A-2-1-1N/A12/31/2019N/A-1N/A0N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: RTGNの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: RTGNの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: RTGNの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: RTGNの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: RTGNの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: RTGNの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 18:15終値2026/05/04 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋RetinalGenix Technologies Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 16RetinalGenix Technologies Inc. announced delayed 10-Q filingOn 05/15/2026, RetinalGenix Technologies Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Mar 31RetinalGenix Technologies Inc. announced delayed annual 10-K filingOn 03/30/2026, RetinalGenix Technologies Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jan 14RetinalGenix Technologies Inc. Reports on Its Science and Mission in Light of New AI-Driven Retinal Mapping StudyRetinalGenix Technologies Inc. announced that a recent large-scale Australian retinal mapping study, which used artificial intelligence to analyze approximately 50,000 retinal scans, reported that specific patterns of retinal thinning are associated with neurodegenerative and metabolic diseases such as dementia, diabetes, and multiple sclerosis. These findings support the broader field of oculomics and reinforce the premise that high-quality retinal images, analyzed with advanced algorithms and integrated with genetic and clinical data, could become an important tool for earlier detection, risk stratification, and ongoing monitoring of disease. If successfully developed, validated, and cleared, these platforms could enable the generation of large-scale, real-world retinal datasets from pharmacies, clinics, urgent care centers, nursing homes, and potentially in-home environments. Such a distributed imaging network could create opportunities for AI-enhanced screening, earlier identification of disease signals, and more proactive patient management, while also providing valuable datasets for research and partnerships with payers, providers, and life sciences companies. The same scientific trends that support the Australian study--convergence of imaging, AI, and genomics--also support RetinalGenix's broader strategy, including programs in remote diagnostics, pharmacogenetic mapping, and therapeutics for conditions such as dry AMD and Alzheimer's-related dementia.
お知らせ • Dec 09+ 1 more updateRetinalGenix Technologies Inc. Appoints M. Cory Zwerling as Chief Financial Officer, Effective January 1, 2026RetinalGenix Technologies Inc. has agreed to hire M. Cory Zwerling as its Chief Financial Officer, effective January 1, 2026. Mr. Zwerling brings more than three decades of global experience in healthcare, finance, and operations across pharmaceuticals, medical imaging, biotechnology, and digital health. Mr. Zwerling brings a distinctive combination of big-pharma P&L leadership, public-company governance, Medtech start-up execution, and hands-on CFO experience across healthcare technology. He has led global pharmaceutical and imaging divisions (President, Bristol-Myers Squibb Medical Imaging and other roles over his 18-year tenure at Bristol-Myers), founded and operated a healthcare IT/AI sleep-diagnostics company (CEO & co-founder, Serenium Inc), served as CEO of a medical-device venture (Zosano Pharmaceuticals), advised multiple health-technology companies, and held a public-company board seat. His background aligns directly with RetinalGenix’s strategic inflection point as the Company seeks to transition from R&D into early commercial operations. His leadership in global marketing, sales, international business management, and finance makes him uniquely equipped to guide the Company through its intended commercial launch while working to ensure disciplined capital deployment and long-term shareholder value creation.
お知らせ • Aug 15RetinalGenix Technologies Inc. announced delayed 10-Q filingOn 08/14/2025, RetinalGenix Technologies Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Feb 21Retinalgenix Technologies Breakthrough in Real-Time 24/7 Remote Ocular MonitoringRetinalGenix Technologies Inc. announced that it has achieved an important milestone in developing its high-resolution retinal imaging device and remote monitoring system. The Company has successfully started imaging patients with its first prototype of its device using both near-infrared and green modes. Additionally, the imaging device simultaneously captures retinal and external images of the patient's eye. A specialized network of retinal specialists will be available to receive the images on a contracted basis, assisting patients who may currently lack an eye care professional to review their results. The device is not intended for diagnostic purposes; rather, it is a screening and monitoring tool. Ex Including patients who are unsuitable for the injections and unlikely to benefit, could avoid any unnecessary complications or morbidity while effectively reducing healthcare expenses. The test should be available to patients at a reasonable cost of approximately $355.00. These factors would make the test invaluable. Over 8 million intraocular injections are performed annually in the United States. Dry AGE-RELATED MACULAR DEGENERATION (AMD) The dry type of AMD affects about 18 million people. It can be painful; infections are common and there is no FDA-approved treatment at this time. The RetinalGenix™? high-resolution retinal imaging system is designed to enable screening for dry macular degeneration in a matter of moments. The scan may be able to assess the severity of the AMD and whether or not it could rapidly progress to the wet type of AMD. RetinalGenix also has been implementing its strategy to identify several opportunities to repurpose FDA-approved pharmaceuticals for the potential benefit of Dry AMD, diabetic retinopathy, and dementia. The Company has submitted provisional patents for these indications in the US and Europe.
お知らせ • Nov 14RetinalGenix Technologies Inc. announced delayed 10-Q filingOn 11/13/2024, RetinalGenix Technologies Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 15RetinalGenix Technologies Inc. announced delayed 10-Q filingOn 08/14/2024, RetinalGenix Technologies Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 18RetinalGenix Technologies Inc. announced delayed 10-Q filingOn 05/16/2024, RetinalGenix Technologies Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Dec 21RetinalGeniX Technologies Inc. Appoints Anatoly Dritschilo, M.D. to the Medical Advisory BoardRetinalGeniX Technologies Inc. announced that Anatoly Dritschilo, M.D. has joined the Company’s Medical Advisory Board. Dr. Dritschilo is a renowned educator, inventor, translational scientist, and business executive. Dr. Dritschilo is the CEO and Chairman of the Board of Directors of Shuttle Pharmaceuticals Holdings Inc. Formerly, as an educator and translational scientist, he was employed at the Georgetown University and the MedStar Georgetown University Hospital as a radiation oncologist and chairman of the Department of Radiation Medicine. Over a 40+ year career, he has provided clinical services to thousands of patients presenting with cancers of the breast, prostate, and the central nervous system. As a translational scientist, Dr. Dritschilo has focused his research on sensitizing cancers to ionizing radiation. He is a leader in the development of antisense oligonucleotides and small molecules directed at targets for radiation sensitization. He has also served as Medical Director of Georgetown University Hospital from 1994 to 1997, and Interim Director of the NCI-funded Lombardi Comprehensive Cancer Center from 2005 to 2007. He has been a member of the Boards of Directors of MedStar-Georgetown University Hospital, the National Capital Rehabilitation Hospital, and the MedStar Research Institute. His 250+ scientific publications and 12 issued patents have earned him election as a Fellow of the National Academy of Inventors. Dr. Dritschilo holds a BS degree in Chemical Engineering from the University of Pennsylvania, his medical degree from the College of Medicine of New Jersey, and residency training from the Harvard Joint Center for Radiation Therapy.
お知らせ • Dec 05RetinalGeniX Technologies Inc. Appoints Dessislava Boneva to its Board of DirectorsRetinalGeniX Technologies Inc. announced that Dessislava (Dessy) Boneva, M.D. has joined the Company’s Board of Directors. Dr. Boneva is an experienced surgeon skilled in trauma, surgical critical care, emergency surgery, and acute care surgery. Dr. Boneva's career began at a specialized Mathematics school where she excelled in Engineering. However, it wasn't until she went on health mission trips that she discovered her true passion for helping patients. She decided to pursue a career in medicine and trained at some of the best schools in the U.S. After completing her surgical residency at an Ivy League school, she was fortunate enough to be trained by some of the best trauma surgeons and leaders in her field, both in the U.S. and around the world. She has dedicated her life to saving lives and helping patients recover from traumatic injuries. With over 10,000 surgeries under her belt, more than 100 publications, and over 20 years of experience in her specialty, she remains just as devoted to the profession as she was when she first started. Dr. Boneva is a faculty member at the University of South Florida (USF) and has received numerous awards throughout her career. She has been included in the Dean's Honor's List, National Dean's List, and Who's Who among students in American Universities and Colleges, as well as the International Who's Who of Professionals. She is actively involved in educating students, residents, and critical care fellows as part of the Graduate Medical Education (GME) programs at her hospital. She is also a Fellow of the American College of Surgeons.
お知らせ • Dec 02RetinalGenix Technologies Inc. Appoints Virender Ahluwalia as Interim Chief Financial OfficerRetinalGeniX Technologies Inc. announced that it has hired Virender Ahluwalia as Interim Chief Financial Officer. Mr. Ahluwalia is a seasoned executive and joins RetinalGeniX Technologies Inc. with over 15 years of experience in finance and operations across public and private organizations. He holds an MBA in Finance from Northeastern University and a Bachelor of Science from the National Institute of Technology (NIT) at Kurukshetra University. His proven track record in high-growth environments includes capital raises and accounting. RetinalGeniX is developing innovative technologies such as DNA/RNA/GPS™ Pharmaco-Genetic Mapping™ software to prevent blindness through the early detection and treatment of ocular diseases.
お知らせ • Nov 29RetinalGenix Technologies Inc. Appoints Stephen Tannenbaum to the Business Advisory BoardRetinalGeniX™ Technologies Inc. announced the addition of Stephen Tannenbaum to the Business Advisory Board of RetinalGeniX. Mr. Tannenbaum will provide strategic business advice, consult on potential mergers and acquisitions, and the development of channels to acquire additional capital for the Company. Mr. Tannenbaum is a seasoned professional in capital markets with a proven track record in raising both equity and debt for public and private companies in special situations. His expertise lies in crafting compelling narratives for capital raises and utilizing resources and knowledge to offer strategic and actionable advice. As a versatile generalist, he has successfully advised and closed transactions across diverse industries, including but not limited to technology, pharmaceuticals, and cannabis. Throughout his investment banking career, he played a pivotal role in raising capital for M&A, equity and debt capital markets, IPOs, and SPACs, specializing in the pharmaceutical and cannabis sectors. He is a distinguished graduate with honors from The Wharton School of The University of Pennsylvania, bringing a unique blend of academic excellence and real-world financial acumen to the table.
お知らせ • Nov 11RetinalGeniX Technologies Inc. Announces the Submission of Two Provisional Patent Applications for Investigational Therapeutic DrugsRetinalGenix Technologies Inc. announced that it has submitted two provisional patent applications to the US Patent Office for its investigational therapeutic drug candidates RTG-2023 and RTG-2024. RTG-2023 is being developed to treat dry age-related macular degeneration (AMD). There are two forms of the disease; wet AMD and dry AMD. Wet macular degeneration is the leading cause of permanent central vision loss. Dry AMD can progress to the wet type if not monitored closely by a doctor. Currently, there are no drugs approved by the FDA that can prevent the dry form of this eye disease from progressing to the wet form or treat the wet form, except through intraocular injections. These direct injections into the eyes are a heavy burden on the patient, both financially and emotionally, and must be administered monthly for the rest of their life. A 2022 study displayed by the National Institutes of Health (NIH PubMed) stated that 200 million people worldwide are estimated to have AMD, and by 2040, this number is projected to rise to close to 300 million. According to the Centers for Disease Control, in 2019, an estimated 19.8 million (12.6%) Americans aged 40 and older were living with age-related macular degeneration (AMD). Of these, 1.49 million (0.94%) were living with (the) vision-threatening (form) RTG-2024 is intended for the treatment of dementia, specifically Alzheimer’s syndrome. According to Alzheimer's Disease International (“ADI”), there are over 55 million people worldwide living with dementia in 2020 and this number is expected to almost double every 20 years, reaching 78 million in 2030 and 139 million in 2050. ADI estimates there are over 10 million new cases of dementia each year worldwide, implying one new case every 3.2 seconds.
お知らせ • Nov 01RetinalGeniX Technologies Inc. Announces Institutional Review Board Approves to Conduct Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular DegenerationRetinalGeniX Technologies Inc. announced the launch of an Institutional Review Board (IRB) for research on its DNA/GPS program. The study aims to offer recommendations for enhancing the preselection process and management of ocular injections. The proposed patient selection process has the potential to reduce the cost and improve the safety and efficacy of patient candidate selection for ocular injections. These factors represent significant challenges associated with wet macular degeneration-related vision loss.
お知らせ • Aug 29RetinalGenix Technologies Inc. Appoints Fred Chasalow to the Medical Advisory Board of DNA-GPSRetinalGenix Technologies Inc. announced the addition of Fred Chasalow, Ph.D., to the Medical Advisory Board of DNA-GPS™. He will also advise RTGN on its other corporate activities. In this capacity, specifically, he will (a) participate in therapeutic drug selection and development and (b) assist in linking high-resolution retinal imaging (RetinalCam™) both to systemic disease and to DNA-GPS™ pharmacogenetic mapping. Dr. Chasalow earned his Ph.D. in biochemistry at Brandeis University. He served as a post-doctoral fellow at ALZA and then as a Senior Research Associate at Columbia P&S with Dr. Seymour Lieberman. From 1977 to 1995, Dr. Chasalow served at several academic appointments, finally ending as Professor of Pediatrics at SUNY, Brooklyn, and Chief of Pediatric Research at Maimonides Medical Center and Director of its Pediatric Endocrine Laboratory. During this period, much of his research included establishing diagnostic methods appropriate for small samples available from infants. In 1991, Dr. Chasalow was appointed as a member of the SuperGen Scientific Advisory Board and played a key role in the scientific development of SuperGen, leading to its successful IPO in 1996. His business experience includes a short stint as an Associate Vice President at Morgan Stanley and 15 years as an independent financial advisor. In 1995, Dr. Chasalow was one of the founders of AMUR Research. It was in his capacity as Chief Scientific Officer that Dr. Chasalow started the investigation that led to the discovery of three novel steroids. Later, AMUR was sold to SuperGen. In 2015, Dr. Chasalow founded IOMA LLC. At IOMA, Dr. Chasalow is credited with discovering three novel steroids. These play a key role in the disease process leading to pre-eclampsia syndrome and, potentially, may lead to its therapy. This spring, Dr. Chasalow sold IOMA to Coddle Creek Capital, where he continues to serve as a consultant.
お知らせ • May 17RetinalGenix Technologies Inc. announced delayed 10-Q filingOn 05/16/2023, RetinalGenix Technologies Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 16RetinalGenix Technologies Inc. announced delayed 10-Q filingOn 11/15/2022, RetinalGenix Technologies Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 16RetinalGenix Technologies Inc. announced delayed 10-Q filingOn 08/15/2022, RetinalGenix Technologies Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jul 27RetinalGenix Technologies Inc. Appoints Vinay Mehindru to its Board of DirectorsRetinalGenix Technologies Inc. announced the appointment of Vinay Mehindru, MD, MBA to the RetinalGenix Technologies Inc. Board of Directors. Dr. Mehindru is a multi-talented top-level executive with over 25 years of healthcare experience. His leadership spans population health and financial performance management. He has led multiple physician performance enhancement strategies and built stakeholder alliances with clinical and financial integration. He is currently serving on the board of directors of Sanovas Inc., SteriView™ Technologies Inc., Intubation Science™, Inc, SinuGeniX™ Inc., OtoGeniX™ Inc., PulmoGeniX™ Technologies Inc., and GastroGeniX™ Inc. Graduating from medical school at age 21, Dr. Mehindru was one of the youngest graduates in his country of birth, India. At age 27, he served on the faculty of the Cleveland Clinic where he was a top-tier internal medicine resident and did research in gastroenterology. Vinay has a second residency from the University of Florida in emergency medicine. Vinay joined a private group of emergency physicians on the east coast of Florida with 47 providers, 75 employees, and over 100,000 annual visits. He has tremendous experience in airway management; working at a level-two trauma center for 10 years. For 16 years, he had been an instructor teaching difficult airway management for both cardiovascular life support and pediatric advanced life support. At the University of Texas at Dallas, he received an Executive MBA with honors, earning the Beta Gamma Sigma Award offered only to the world’s top 5% of business students. Dr. Mehindru is the Founder & CEO of Exemplary Health. With AdventHealth he has been a Chief Medical Officer and was President of AdventHealth’s Physician Network, Tampa Bay.
お知らせ • Jul 08RetinalGenix Technologies Inc. (OTCPK:RTGN) acquired DNA/GPS Inc. from Lawrence Perich.RetinalGenix Technologies Inc. (OTCPK:RTGN) acquired DNA/GPS Inc. from Lawrence Perich for $14 million on July 5, 2022. RetinalGenix Technologies Inc. acquired all the outstanding shares of DNA/GPS Inc. in exchange for the issuance of 2,000,000 shares of the Company’s common stock. Larry Perich, Founder of DNA/GPS Inc., will join the advisory board of RetinalGenix Technologies Inc. Leslie Marlow of Blank Rome LLP acted as legal advisor to RetinalGenix Technologies Inc. Ken Zuckerbrot of Greenberg Traurig, LLP acted as legal advisor to DNA/GPS Inc. RetinalGenix Technologies Inc. (OTCPK:RTGN) completed the acquisition of DNA/GPS Inc. from Lawrence Perich on July 5, 2022.
お知らせ • Apr 01RetinalGenix Technologies Inc. announced delayed annual 10-K filingOn 03/31/2022, RetinalGenix Technologies Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.